RT Journal Article
T1 Allergoid–mannan conjugates reprogram monocytes into tolerogenic dendritic cells via epigenetic and metabolic rewiring
A1 Benito Villalvilla, Cristina
A1 Pérez Diego, Mario
A1 Angelina Querencias, Alba
A1 Kisand, Kai
A1 Rebane, Ana
A1 Subiza, José Luis
A1 Palomares Gracia, Óscar
AB Allergoid–mannan conjugates are novel vaccines for allergen-specific immunotherapy being currently assayed in phase 2 clinical trials. Allergoid–mannan conjugates target dendritic cells (DCs) and generate functional forkhead box P3 (FOXP3)-positive Treg cells, but their capacity to reprogram monocyte differentiation remains unknown.
PB Elsevier
SN 0091-6749
YR 2022
FD 2022-06-18
LK https://hdl.handle.net/20.500.14352/71283
UL https://hdl.handle.net/20.500.14352/71283
LA eng
NO CRUE-CSIC (Acuerdos Transformativos 2021)
NO Ministerio de Economía y Competitividad (MINECO)
NO Fondo Europeo de Desarrollo Regional (FEDER)
NO Estonian Research Council
DS Docta Complutense
RD 10 abr 2025